Monocyte intracellular cytokine production during human endotoxaemia with or without a secondin vitroLPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness
| Autor: | J. E. Tulleken, M. M. Faas, Jan G. Zijlstra, A. C. Muller Kobold, H. Moes, J W Fijen |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Lipopolysaccharides
Male Chemokine medicine.medical_specialty Lipopolysaccharide Pyridines medicine.medical_treatment Immunology p38 Mitogen-Activated Protein Kinases Monocytes chemistry.chemical_compound In vivo White blood cell Internal medicine medicine Humans Immunology and Allergy Enzyme Inhibitors biology Tumor Necrosis Factor-alpha Monocyte Imidazoles Original Articles Interleukin-12 Shock Septic Endotoxemia Endocrinology medicine.anatomical_structure Cytokine Gene Expression Regulation chemistry biology.protein Interleukin 12 lipids (amino acids peptides and proteins) Tumor necrosis factor alpha Mitogen-Activated Protein Kinases Interleukin-1 |
| Zdroj: | Clinical and Experimental Immunology. 127:337-343 |
| ISSN: | 1365-2249 0009-9104 |
| Popis: | SummaryIn the present study, we investigated the effect of RWJ-67657, a p38 MAP kinase inhibitor, upon in vivo LPS-induced monocyte cytokine production and upon monocyte LPS-hyporesponsiveness. Thirty minutes before a single injection of LPS (4 ng/kg BW), healthy male volunteers received a single oral dose of RWJ-67657 at increasing dosages (0–1400 mg). Blood samples (pre-medication, 3, 6 and 24 h after LPS) were immediately incubated with LPS (reflecting LPS-hyporesponsiveness) or without LPS (reflecting in vivo monocyte stimulation) for 4 h at 37°C. Following red blood cells lysis and white blood cell permeabilization, cells were labelled with α-CD14-FITC and α-IL-1β, α-IL-12 or α-TNFα (PE-labelled), fixed, and analysed using flow cytometry. In vivo LPS injection resulted in an increased percentage of circulating monocytes producing IL-1β, TNFα and IL-12 only at 3 h after the LPS injection. This was dose-dependently inhibited by RWJ-67657 treatment. LPS-hyporesponsiveness to in vitro LPS treatment was most prominent at 3 and 6 h after the in vivo LPS injection; compared with pre-medication monocytes, at these intervals a reduced percentage of monocytes produced IL-1β, TNFα or IL-12 after the in vitro LPS stimulus. At t = 6 h, this LPS-hyporesponsiveness could dose-dependently be inhibited by RWJ-67657 treatment of the volunteers. We therefore conclude that p38 MAP kinase inhibition with RWJ-67657 inhibited monocyte production of cytokines following in vivo LPS injection. Treatment with RWJ-67657 also reversed the LPS-hyporesponsiveness. Whether this result can be extended to the clinical situation remains to be elucidated. Patients with sepsis or an otherwise high risk for multi-organ failure are potential study groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|